Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(3):261–269. doi: 10.1038/bjc.1996.47

The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene.

C C Harris 1
PMCID: PMC2074430  PMID: 8562328

Full text

PDF
261

Images in this article

266Figure 6
on p.266

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar F., Harris C. C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 1994 May 27;264(5163):1317–1319. doi: 10.1126/science.8191284. [DOI] [PubMed] [Google Scholar]
  2. Aguilar F., Hussain S. P., Cerutti P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586–8590. doi: 10.1073/pnas.90.18.8586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bakalkin G., Yakovleva T., Selivanova G., Magnusson K. P., Szekely L., Kiseleva E., Klein G., Terenius L., Wiman K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):413–417. doi: 10.1073/pnas.91.1.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990 Aug 24;249(4971):912–915. doi: 10.1126/science.2144057. [DOI] [PubMed] [Google Scholar]
  5. Barrett J. C., Wiseman R. W. Molecular carcinogenesis in humans and rodents. Prog Clin Biol Res. 1992;376:1–30. [PubMed] [Google Scholar]
  6. Benn J., Schneider R. J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10350–10354. doi: 10.1073/pnas.91.22.10350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brash D. E., Rudolph J. A., Simon J. A., Lin A., McKenna G. J., Baden H. P., Halperin A. J., Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124–10128. doi: 10.1073/pnas.88.22.10124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brennan J. A., Boyle J. O., Koch W. M., Goodman S. N., Hruban R. H., Eby Y. J., Couch M. J., Forastiere A. A., Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995 Mar 16;332(11):712–717. doi: 10.1056/NEJM199503163321104. [DOI] [PubMed] [Google Scholar]
  9. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429–431. doi: 10.1038/350429a0. [DOI] [PubMed] [Google Scholar]
  10. Cariello N. F., Cui L., Beroud C., Soussi T. Database and software for the analysis of mutations in the human p53 gene. Cancer Res. 1994 Aug 15;54(16):4454–4460. [PubMed] [Google Scholar]
  11. Caselmann W. H., Meyer M., Kekulé A. S., Lauer U., Hofschneider P. H., Koshy R. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2970–2974. doi: 10.1073/pnas.87.8.2970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chen P. L., Chen Y. M., Bookstein R., Lee W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 1990 Dec 14;250(4987):1576–1580. doi: 10.1126/science.2274789. [DOI] [PubMed] [Google Scholar]
  13. Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346–355. doi: 10.1126/science.8023157. [DOI] [PubMed] [Google Scholar]
  14. Clore G. M., Omichinski J. G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 1994 Jul 15;265(5170):386–391. doi: 10.1126/science.8023159. [DOI] [PubMed] [Google Scholar]
  15. Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S. J., Vogelstein B. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990 Nov;10(11):5772–5781. doi: 10.1128/mcb.10.11.5772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A. K., Moore M., Finlay C., Levine A. J. Gain of function mutations in p53. Nat Genet. 1993 May;4(1):42–46. doi: 10.1038/ng0593-42. [DOI] [PubMed] [Google Scholar]
  17. Dumaz N., Stary A., Soussi T., Daya-Grosjean L., Sarasin A. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat Res. 1994 May 1;307(1):375–386. doi: 10.1016/0027-5107(94)90311-5. [DOI] [PubMed] [Google Scholar]
  18. Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O., Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763–8767. doi: 10.1073/pnas.86.22.8763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Evans M. K., Taffe B. G., Harris C. C., Bohr V. A. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res. 1993 Nov 15;53(22):5377–5381. [PubMed] [Google Scholar]
  20. Feitelson M. A., Zhu M., Duan L. X., London W. T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993 May;8(5):1109–1117. [PubMed] [Google Scholar]
  21. Fields S., Jang S. K. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990 Aug 31;249(4972):1046–1049. doi: 10.1126/science.2144363. [DOI] [PubMed] [Google Scholar]
  22. Finlay C. A., Hinds P. W., Levine A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989 Jun 30;57(7):1083–1093. doi: 10.1016/0092-8674(89)90045-7. [DOI] [PubMed] [Google Scholar]
  23. Forrester K., Lupold S. E., Ott V. L., Chay C. H., Band V., Wang X. W., Harris C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 1995 Jun 1;10(11):2103–2111. [PubMed] [Google Scholar]
  24. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  25. Harris C. C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res. 1991 Sep 15;51(18 Suppl):5023s–5044s. [PubMed] [Google Scholar]
  26. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  27. Harris C. C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980–1981. doi: 10.1126/science.8266092. [DOI] [PubMed] [Google Scholar]
  28. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700–9704. doi: 10.1073/pnas.91.21.9700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hino O., Nomura K., Ohtake K., Kawaguchi T., Sugano H., Kitagawa T. Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. Cancer Genet Cytogenet. 1989 Feb;37(2):273–278. doi: 10.1016/0165-4608(89)90059-9. [DOI] [PubMed] [Google Scholar]
  30. Hino O., Tabata S., Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9248–9252. doi: 10.1073/pnas.88.20.9248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
  32. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  33. Hsiao M., Low J., Dorn E., Ku D., Pattengale P., Yeargin J., Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994 Sep;145(3):702–714. [PMC free article] [PubMed] [Google Scholar]
  34. Hsu I. C., Metcalf R. A., Sun T., Welsh J. A., Wang N. J., Harris C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991 Apr 4;350(6317):427–428. doi: 10.1038/350427a0. [DOI] [PubMed] [Google Scholar]
  35. Hupp T. R., Lane D. P. Allosteric activation of latent p53 tetramers. Curr Biol. 1994 Oct 1;4(10):865–875. doi: 10.1016/s0960-9822(00)00195-0. [DOI] [PubMed] [Google Scholar]
  36. Jayaraman J., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 1995 Jun 30;81(7):1021–1029. doi: 10.1016/s0092-8674(05)80007-8. [DOI] [PubMed] [Google Scholar]
  37. Jeffrey P. D., Gorina S., Pavletich N. P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995 Mar 10;267(5203):1498–1502. doi: 10.1126/science.7878469. [DOI] [PubMed] [Google Scholar]
  38. Jego N., Thomas G., Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene. 1993 Jan;8(1):209–213. [PubMed] [Google Scholar]
  39. Kekulé A. S., Lauer U., Meyer M., Caselmann W. H., Hofschneider P. H., Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature. 1990 Feb 1;343(6257):457–461. doi: 10.1038/343457a0. [DOI] [PubMed] [Google Scholar]
  40. Krawczak M., Cooper D. N. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet. 1991 Mar;86(5):425–441. doi: 10.1007/BF00194629. [DOI] [PubMed] [Google Scholar]
  41. Kunkel T. A. Nucleotide repeats. Slippery DNA and diseases. Nature. 1993 Sep 16;365(6443):207–208. doi: 10.1038/365207a0. [DOI] [PubMed] [Google Scholar]
  42. Lee W., Harvey T. S., Yin Y., Yau P., Litchfield D., Arrowsmith C. H. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol. 1994 Dec;1(12):877–890. doi: 10.1038/nsb1294-877. [DOI] [PubMed] [Google Scholar]
  43. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  44. Levine A. J., Perry M. E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994 Mar;69(3):409–416. doi: 10.1038/bjc.1994.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Li D., Cao Y., He L., Wang N. J., Gu J. R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 1993 Feb;14(2):169–173. doi: 10.1093/carcin/14.2.169. [DOI] [PubMed] [Google Scholar]
  46. Li F. P., Garber J. E., Friend S. H., Strong L. C., Patenaude A. F., Juengst E. T., Reilly P. R., Correa P., Fraumeni J. F., Jr Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst. 1992 Aug 5;84(15):1156–1160. doi: 10.1093/jnci/84.15.1156. [DOI] [PubMed] [Google Scholar]
  47. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994 May 15;8(10):1235–1246. doi: 10.1101/gad.8.10.1235. [DOI] [PubMed] [Google Scholar]
  48. Liu X., Miller C. W., Koeffler P. H., Berk A. J. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol. 1993 Jun;13(6):3291–3300. doi: 10.1128/mcb.13.6.3291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Lu H., Levine A. J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A. 1995 May 23;92(11):5154–5158. doi: 10.1073/pnas.92.11.5154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Mack D. H., Vartikar J., Pipas J. M., Laimins L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 1993 May 20;363(6426):281–283. doi: 10.1038/363281a0. [DOI] [PubMed] [Google Scholar]
  51. Maguire H. F., Hoeffler J. P., Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science. 1991 May 10;252(5007):842–844. doi: 10.1126/science.1827531. [DOI] [PubMed] [Google Scholar]
  52. Martin D. W., Muñoz R. M., Subler M. A., Deb S. p53 binds to the TATA-binding protein-TATA complex. J Biol Chem. 1993 Jun 25;268(18):13062–13067. [PubMed] [Google Scholar]
  53. Mercer W. E., Shields M. T., Amin M., Sauve G. J., Appella E., Romano J. W., Ullrich S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166–6170. doi: 10.1073/pnas.87.16.6166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Paterlini P., Poussin K., Kew M., Franco D., Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995 Feb;21(2):313–321. [PubMed] [Google Scholar]
  55. Ponchel F., Puisieux A., Tabone E., Michot J. P., Fröschl G., Morel A. P., Frébourg T., Fontanière B., Oberhammer F., Ozturk M. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res. 1994 Apr 15;54(8):2064–2068. [PubMed] [Google Scholar]
  56. Prives C. How loops, beta sheets, and alpha helices help us to understand p53. Cell. 1994 Aug 26;78(4):543–546. doi: 10.1016/0092-8674(94)90519-3. [DOI] [PubMed] [Google Scholar]
  57. Raycroft L., Wu H. Y., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31;249(4972):1049–1051. doi: 10.1126/science.2144364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Ripley L. S. Frameshift mutation: determinants of specificity. Annu Rev Genet. 1990;24:189–213. doi: 10.1146/annurev.ge.24.120190.001201. [DOI] [PubMed] [Google Scholar]
  59. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D. A., Smith S., Uziel T., Sfez S. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995 Jun 23;268(5218):1749–1753. doi: 10.1126/science.7792600. [DOI] [PubMed] [Google Scholar]
  60. Scorsone K. A., Zhou Y. Z., Butel J. S., Slagle B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res. 1992 Mar 15;52(6):1635–1638. [PubMed] [Google Scholar]
  61. Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12028–12032. doi: 10.1073/pnas.89.24.12028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Shields P. G., Harris C. C. Molecular epidemiology and the genetics of environmental cancer. JAMA. 1991 Aug 7;266(5):681–687. [PubMed] [Google Scholar]
  63. Shirakata Y., Kawada M., Fujiki Y., Sano H., Oda M., Yaginuma K., Kobayashi M., Koike K. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res. 1989 Jul;80(7):617–621. doi: 10.1111/j.1349-7006.1989.tb01686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Soussi T., Caron de Fromentel C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 1990 Jul;5(7):945–952. [PubMed] [Google Scholar]
  65. Spandau D. F., Lee C. H. trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol. 1988 Feb;62(2):427–434. doi: 10.1128/jvi.62.2.427-434.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Thut C. J., Chen J. L., Klemm R., Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science. 1995 Jan 6;267(5194):100–104. doi: 10.1126/science.7809597. [DOI] [PubMed] [Google Scholar]
  67. Tornaletti S., Pfeifer G. P. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science. 1994 Mar 11;263(5152):1436–1438. doi: 10.1126/science.8128225. [DOI] [PubMed] [Google Scholar]
  68. Truant R., Xiao H., Ingles C. J., Greenblatt J. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem. 1993 Feb 5;268(4):2284–2287. [PubMed] [Google Scholar]
  69. Twu J. S., Schloemer R. H. Transcriptional trans-activating function of hepatitis B virus. J Virol. 1987 Nov;61(11):3448–3453. doi: 10.1128/jvi.61.11.3448-3453.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Ueda H., Ullrich S. J., Gangemi J. D., Kappel C. A., Ngo L., Feitelson M. A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995 Jan;9(1):41–47. doi: 10.1038/ng0195-41. [DOI] [PubMed] [Google Scholar]
  71. Unsal H., Yakicier C., Marçais C., Kew M., Volkmann M., Zentgraf H., Isselbacher K. J., Ozturk M. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):822–826. doi: 10.1073/pnas.91.2.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Vogelstein B., Kinzler K. W. Carcinogens leave fingerprints. Nature. 1992 Jan 16;355(6357):209–210. doi: 10.1038/355209a0. [DOI] [PubMed] [Google Scholar]
  73. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  74. Wang X. W., Forrester K., Yeh H., Feitelson M. A., Gu J. R., Harris C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2230–2234. doi: 10.1073/pnas.91.6.2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Wang X. W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J. M., Wang Z., Freidberg E. C., Evans M. K., Taffe B. G. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet. 1995 Jun;10(2):188–195. doi: 10.1038/ng0695-188. [DOI] [PubMed] [Google Scholar]
  76. Wink D. A., Kasprzak K. S., Maragos C. M., Elespuru R. K., Misra M., Dunams T. M., Cebula T. A., Koch W. H., Andrews A. W., Allen J. S. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1991 Nov 15;254(5034):1001–1003. doi: 10.1126/science.1948068. [DOI] [PubMed] [Google Scholar]
  77. Ziegler A., Jonason A. S., Leffell D. J., Simon J. A., Sharma H. W., Kimmelman J., Remington L., Jacks T., Brash D. E. Sunburn and p53 in the onset of skin cancer. Nature. 1994 Dec 22;372(6508):773–776. doi: 10.1038/372773a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES